A Phase 2 interventional study of Emraclidine 15 mg and Emraclidine 30 mg in Schizophrenia, sponsored by AbbVie. Completed at 26 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-28.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Schizophrenia by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · AbbVie.
Among the 27 studies in Schizophrenia by AbbVie, this one is the 9th largest by enrollment, is one of 5 that started in 2022, is one of 13 in phase 2, and was the 22nd registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 27 studies in Schizophrenia by AbbVie is open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 391 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 268 across the 27 interventional studies. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Schizophrenia by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in male and female adult participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
The trial included up to a 15-day Screening Period (up to a maximum of 21 days allowed with approval of the medical monitor), a 45-day Inpatient Treatment Period, and a 28-day Follow-up Period. Each participant participated in the trial for up to approximately 13 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following:
Any of the following regarding history of schizophrenia:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Dose
Drug: Emraclidine 15 mg
Oral Dose
Drug: Emraclidine 30 mg
Oral Dose
Drug: Placebo
Emraclidine 15 mg, oral (tablet), once per day (QD) for 6 weeks
Also known as: CVL-231, ABBV-1231
Emraclidine 30 mg, oral (tablet), QD for 6 weeks
Also known as: CVL-231, ABBV-1231
Matching placebo, oral (tablet), QD for 6 weeks
Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. Baseline was defined as the last value obtained prior to initiation of investigational medicinal product (IMP). Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
Time frame: Baseline through Week 6
Change From Baseline at Week 6 in the Clinical Global Impression - Severity (CGI-S Score)
The CGI-S captures clinician's response to: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Baseline was defined as the last value obtained prior to initiation of investigational medicinal product (IMP). Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. Negative changes from Baseline indicate less mental illness.
Time frame: Baseline through Week 6
Change From Baseline at All Time Points in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. Baseline was defined as the last value obtained prior to initiation of investigational medicinal product (IMP). Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
Time frame: Baseline; Weeks 1, 2, 3, 4, 5, and 6
Change From Baseline at All Time Points in the Clinical Global Impression - Severity (CGI-S) Score
The CGI-S captures clinician's response to: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Baseline was defined as the last value obtained prior to initiation of Emraclidine. Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. Negative changes from Baseline indicate less mental illness.
Time frame: Baseline; Weeks 1, 2, 3, 4, 5, and 6
Percentage of Responders at Week 6 (Responders Defined as ≥30% Reduction From Baseline in PANSS Total Score)
The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. A PANSS responder is defined as a participant with at least a 30% change in PANSS total score compared to baseline at Week 6 or the early termination visit. If a subject discontinued and did not have an early termination visit, the subject's last assessment was considered.
Time frame: Baseline through Week 6
Number of Participants With Treatment Emergent Adverse Event (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: From first dose of study drug until 28 days following last dose of study drug (up to Week 10)
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECGs)
Assessment of clinically significant changes in electrocardiogram measures measured by 12-lead ECG recording after the participant has been supine and at rest for at least 3 minutes.
Time frame: Baseline; from first dose of study drug up to Week 6
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes.
Time frame: Baseline; from first dose of study drug up to Week 6
Number of Participants With Clinically Significant Changes in Vital Sign Measurements
Vital signs were obtained after the participant had been supine and at rest for 3 minutes and included temperature, systolic and diastolic blood pressure, respiratory rate, and heart rate. Participants' body weights were also measured and recorded.
Time frame: Baseline; from first dose of study drug up to Week 6
Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results
The number of participants with clinically significant changes in physical and neurological examination results was documented.
Time frame: Baseline; from first dose of study drug up to Week 6
Number of Participants With Suicide-Related Treatment-Emergent Events Assessed Using the Columbia Suicide-Severity Rating Scale (C-SSRS)
The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).
Time frame: Baseline; from first dose of study drug up to Week 6
Change From Baseline in Simpson Angus Scale (SAS) Total Score
The SAS consists of a list of 10 symptoms of parkinsonism. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items. Baseline was defined as the last value obtained prior to initiation of study drug. Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. Negative changes from Baseline indicate an improvement in symptoms.
Time frame: Baseline; Weeks 3 and 6
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Rating Score
The Abnormal Involuntary Movement Scale assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the participant is at rest, and the investigator also makes global judgments on the participant's dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the participant's dental status. The AIMS Movement Rating Score is defined as the sum of individual scores from items 1-7, ranging from 0 to 28. A lower score indicates less severe or absent abnormal movements. A negative change in the mean from baseline indicates improvement in the severity of abnormal involuntary movements.
Time frame: Baseline; Weeks 3 and 6
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Evaluation Score
The BARS consists of 4 items related to akathisia: The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The fourth item, reported here, is the Global Clinical Evaluation Score. The Global Clinical Evaluation Score is evaluated using a 6-point scale, with a score of 0 representing the absence of symptoms and a score of 5 representing severe akathisia. A negative change from baseline indicates an improvement in symptoms.
Time frame: Baseline; Weeks 3 and 6
Participants were randomly assigned at a ratio of 1:1:1 to one of three treatment groups (Emraclidine 15 mg QD, Emraclidine 30 mg QD, or Placebo). Randomization was stratified by geographic region (United States or all other countries).
| Milestone | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Started | 130 | 130 | 131 |
| Completed | 102 | 93 | 93 |
| Not completed | 28 | 37 | 38 |
| Withdrew: Adverse event | 2 | 6 | 4 |
| Withdrew: Lack of efficacy | 4 | 0 | 1 |
| Withdrew: Physician decision | 2 | 2 | 1 |
| Withdrew: Protocol violation | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 17 | 26 | 32 |
| Withdrew: Non-compliance with study schedule | 0 | 1 | 0 |
| Withdrew: Other | 1 | 1 | 0 |
The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. Baseline was defined as the last value obtained prior to initiation of investigational medicinal product (IMP). Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
| score on a scale | Placebo | Emraclidine 15mg QD | Emraclidine 30mg QD |
|---|---|---|---|
| Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score | -16.1 (-19.4 to -12.8) | -18.5 (-22.0 to -15.0) | -14.2 (-17.5 to -10.8) |
The CGI-S captures clinician's response to: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Baseline was defined as the last value obtained prior to initiation of investigational medicinal product (IMP). Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. Negative changes from Baseline indicate less mental illness.
| score on a scale | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Change From Baseline at Week 6 in the Clinical Global Impression - Severity (CGI-S Score) | -0.83 (-1.03 to -0.64) | -1.05 (-1.25 to -0.84) | -0.80 (-1.00 to -0.60) |
The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. Baseline was defined as the last value obtained prior to initiation of investigational medicinal product (IMP). Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
| score on a scale | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Week 1 | -5.0 (-6.9 to -3.1) | -6.8 (-8.8 to -4.8) | -4.9 (-6.8 to -2.9) |
| Week 2 | -8.5 (-10.9 to -6.1) | -8.7 (-11.2 to -6.3) | -7.5 (-9.9 to -5.1) |
| Week 3 | -11.2 (-13.8 to -8.5) | -12.5 (-15.3 to -9.7) | -10.0 (-12.6 to -7.3) |
| Week 4 | -12.8 (-15.5 to -10.1) | -13.4 (-16.3 to -10.5) | -12.0 (-14.8 to -9.2) |
| Week 5 | -14.7 (-17.7 to -11.6) | -16.5 (-19.7 to -13.2) | -12.9 (-16.0 to -9.8) |
| Week 6 | -16.1 (-19.4 to -12.8) | -18.5 (-22.0 to -15.0) | -14.2 (-17.5 to -10.8) |
The CGI-S captures clinician's response to: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Baseline was defined as the last value obtained prior to initiation of Emraclidine. Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. Negative changes from Baseline indicate less mental illness.
| score on a scale | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Week 1 | -0.21 (-0.33 to -0.09) | -0.33 (-0.46 to -0.21) | -0.21 (-0.33 to -0.09) |
| Week 2 | -0.42 (-0.56 to -0.28) | -0.42 (-0.56 to -0.27) | -0.38 (-0.52 to -0.24) |
| Week 3 | -0.55 (-0.70 to -0.40) | -0.64 (-0.80 to -0.48) | -0.49 (-0.64 to -0.34) |
| Week 4 | -0.72 (-0.88 to -0.55) | -0.74 (-0.91 to -0.57) | -0.62 (-0.79 to -0.46) |
| Week 5 | -0.78 (-0.96 to -0.60) | -0.91 (-1.10 to -0.72) | -0.69 (-0.87 to -0.51) |
| Week 6 | -0.83 (-1.03 to -0.64) | -1.05 (-1.25 to -.084) | -0.80 (-1.00 to -0.60) |
The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. A PANSS responder is defined as a participant with at least a 30% change in PANSS total score compared to baseline at Week 6 or the early termination visit. If a subject discontinued and did not have an early termination visit, the subject's last assessment was considered.
| percentage of participants | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Percentage of Responders at Week 6 (Responders Defined as ≥30% Reduction From Baseline in PANSS Total Score) | 19.5 | 23.8 | 12.2 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
| Participants | Placebo | Emraclidine 15mg QD | Emraclidine 30mg QD |
|---|---|---|---|
| Any TEAE | 69 | 65 | 65 |
| TESAE | 1 | 3 | 1 |
Assessment of clinically significant changes in electrocardiogram measures measured by 12-lead ECG recording after the participant has been supine and at rest for at least 3 minutes.
| Participants | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| QTcF value: > 450 - 480 msec | 3 | 1 | 3 |
| QTcF value: > 480 - 500 msec | 1 | 0 | 0 |
| QTcF value: > 500 msec | 0 | 0 | 0 |
| QTcF increase from baseline: > 30 - 60 msec | 7 | 10 | 10 |
| QTcF increase from baseline: > 60 msec | 1 | 1 | 1 |
Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes.
| Participants | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments | 3 | 4 | 3 |
Vital signs were obtained after the participant had been supine and at rest for 3 minutes and included temperature, systolic and diastolic blood pressure, respiratory rate, and heart rate. Participants' body weights were also measured and recorded.
| Participants | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Supine Systolic Blood Pressure: < 90 mmHg | 0 | 0 | 0 |
| Supine Systolic Blood Pressure: > 140 mmHg and ≤ 160 mmHg | 10 | 10 | 19 |
| Supine Systolic Blood Pressure: 160 mmHg and ≤ 200 mmHg | 0 | 0 | 0 |
| Supine Systolic Blood Pressure: > 200 mmHg | 0 | 0 | 0 |
| Orthostatic Change in Systolic Blood Pressure: ≥ 20 mmHg decrease | 4 | 1 | 2 |
| Supine Diastolic Blood Pressure: < 50 mmHg | 0 | 0 | 0 |
| Supine Diastolic Blood Pressure: > 90 mmHg and ≤ 100 mmHg | 5 | 12 | 19 |
| Supine Diastolic Blood Pressure: > 100 mmHg and ≤ 120 mmHg | 0 | 1 | 1 |
| Supine Diastolic Blood Pressure: > 120 mmHg | 0 | 0 | 0 |
| Orthostatic Change in Diastolic Blood Pressure: ≥ 10 mmHg decrease | 3 | 12 | 5 |
| Supine Heart Rate: < 50 bpm | 0 | 2 | 0 |
| Supine Heart Rate: ≥ 50 bpm and < 60 bpm | 19 | 12 | 8 |
| Supine Heart Rate: > 100 bpm and ≤ 120 bpm | 5 | 20 | 16 |
| Supine Heart Rate: > 120 bpm | 0 | 0 | 1 |
| Temperature: < 36 °C | 2 | 5 | 4 |
| Temperature: > 38 °C | 2 | 0 | 0 |
| Respiratory Rate: < 12 breaths/min | 0 | 1 | 0 |
| Respiratory Rate: > 20 breaths/min | 3 | 1 | 3 |
| Weight: ≥ 7% decrease | 6 | 0 | 4 |
| Weight: ≥ 7% increase | 8 | 13 | 13 |
The number of participants with clinically significant changes in physical and neurological examination results was documented.
| Participants | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Clinically Significant Changes in Physical Examination | 1 | 1 | 0 |
| Clinically Significant Changes in Neurological Examination | 3 | 3 | 0 |
The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).
| Participants | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Treatment-Emergent Suicidal Ideation Compared to Recent History | 3 | 5 | 2 |
| Treatment-Emergent Serious Suicidal Ideation Compared to Recent History | 0 | 0 | 0 |
| Emergence of Serious Suicidal Ideation Compared to Recent History | 0 | 0 | 0 |
| Emergence of Suicidal Behavior Compared to all Prior History | 0 | 0 | 0 |
The SAS consists of a list of 10 symptoms of parkinsonism. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items. Baseline was defined as the last value obtained prior to initiation of study drug. Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. Negative changes from Baseline indicate an improvement in symptoms.
| score on a scale | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Week 3 | -0.1 (-0.1 to 0.0) | 0.0 (-0.1 to 0.1) | 0.0 (0.0 to 0.1) |
| Week 6 | 0.0 (-0.1 to 0.1) | 0.0 (0.0 to 0.1) | 0.0 (-0.1 to 0.1) |
The Abnormal Involuntary Movement Scale assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the participant is at rest, and the investigator also makes global judgments on the participant's dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the participant's dental status. The AIMS Movement Rating Score is defined as the sum of individual scores from items 1-7, ranging from 0 to 28. A lower score indicates less severe or absent abnormal movements. A negative change in the mean from baseline indicates improvement in the severity of abnormal involuntary movements.
| score on a scale | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Week 3 | 0.0 (0.0 to 0.1) | 0.0 (-0.1 to 0.1) | 0.0 (-0.1 to 0.1) |
| Week 6 | 0.0 (0.0 to 0.1) | 0.0 (-0.1 to 0.0) | 0.0 (0.0 to 0.1) |
The BARS consists of 4 items related to akathisia: The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The fourth item, reported here, is the Global Clinical Evaluation Score. The Global Clinical Evaluation Score is evaluated using a 6-point scale, with a score of 0 representing the absence of symptoms and a score of 5 representing severe akathisia. A negative change from baseline indicates an improvement in symptoms.
| score on a scale | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD |
|---|---|---|---|
| Week 3 | 0.0 (-0.1 to 0.0) | 0.0 (-0.1 to 0.0) | 0.0 (-0.1 to 0.0) |
| Week 6 | -0.1 (-0.1 to 0.0) | 0.0 (0.0 to 0.1) | 0.0 (-0.1 to 0.0) |
Collected over All-cause mortality and adverse event tables include events reported from the time informed consent was signed to the end of the study. The median time on follow-up was 80 days for the Placebo group, 67.5 days for the Emraclidine 15 mg group, and 64.0 days for the Emraclidine 30 mg group.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/130 (0%) | 1/130 (0.8%) | 47/130 (36.2%) |
| Emraclidine 15mg QD | 0/130 (0%) | 3/130 (2.3%) | 47/130 (36.2%) |
| Emraclidine 30mg QD | 0/131 (0%) | 1/131 (0.8%) | 50/131 (38.2%) |
| Event | Placebo | Emraclidine 15mg QD | Emraclidine 30mg QD |
|---|---|---|---|
| VISION BLURREDEye disorders | 0/130 | 1/130 | 0/131 |
| HEADACHENervous system disorders | 0/130 | 1/130 | 0/131 |
| NEUROLEPTIC MALIGNANT SYNDROMENervous system disorders | 1/130 | 0/130 | 0/131 |
| ACUTE PSYCHOSISPsychiatric disorders | 0/130 | 1/130 | 0/131 |
| PSYCHOTIC DISORDERPsychiatric disorders | 0/130 | 1/130 | 0/131 |
| SCHIZOPHRENIAPsychiatric disorders | 0/130 | 1/130 | 0/131 |
| AGITATIONPsychiatric disorders | 0/130 | 0/130 | 1/131 |
| Event | Placebo | Emraclidine 15mg QD | Emraclidine 30mg QD |
|---|---|---|---|
| HEADACHENervous system disorders | 14/130 | 18/130 | 17/131 |
| WEIGHT INCREASEDInvestigations | 5/130 | 11/130 | 4/131 |
| DRY MOUTHGastrointestinal disorders | 1/130 | 1/130 | 7/131 |
| CONSTIPATIONGastrointestinal disorders | 2/130 | 6/130 | 3/131 |
| NAUSEAGastrointestinal disorders | 5/130 | 6/130 | 4/131 |
| TOOTHACHEGastrointestinal disorders | 6/130 | 3/130 | 2/131 |
| SOMNOLENCENervous system disorders | 6/130 | 4/130 | 4/131 |
| SINUS TACHYCARDIACardiac disorders | 0/130 | 4/130 | 0/131 |
| ABDOMINAL DISCOMFORTGastrointestinal disorders | 3/130 | 4/130 | 0/131 |
| DYSPEPSIAGastrointestinal disorders | 2/130 | 4/130 | 3/131 |
Intent-to-treat (ITT) population: all randomized participants
| Age, Continuous(years) | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD | Total |
|---|---|---|---|---|
| Mean | 42.1 ± 12.18 | 42.7 ± 11.51 | 41.5 ± 10.76 | 42.1 ± 11.48 |
| Sex: Female, Male(Participants) | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD | Total |
|---|---|---|---|---|
| Female | 27 | 34 | 25 | 86 |
| Male | 103 | 96 | 106 | 305 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 30 | 25 | 25 | 80 |
| Not Hispanic or Latino | 100 | 105 | 106 | 311 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Emraclidine 15 mg QD | Emraclidine 30 mg QD | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 76 | 83 | 85 | 244 |
| White | 53 | 44 | 44 | 141 |
| More than one race | 0 | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2022 to primary completion in Aug 2024, 25 months.
Results were first posted in Oct 2025, 1 year 2 months after primary completion. A results delay was requested in Apr 2025.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 25 months is above that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emraclidine